Em recrutamento
FASE
Número Europeu 2022-501697-19
MK-1026-011/BELLWAVE-011
A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)
Detalhes
Destaques